Gerd Luippold

Gerd Luippold is a seasoned professional in the pharmaceutical industry, currently serving as TA Head Cardiometabolic, CNS, and Retinal Health in Early Clinical Trials and Head of Early Clinical Operations at Boehringer Ingelheim since April 2021. Prior to this role, Gerd Luippold held the position of Clinical Trial Leader from June 2018 to April 2021 and Lab Leader focused on preclinical studies in Cardiometabolic Research from July 2006 to May 2018 at Boehringer Ingelheim Pharma GmbH & Co. KG. Gerd Luippold's academic background includes a Doctor of Medicine (MD) from the University of Tübingen and a Pharmacy degree from the same institution. Additionally, Gerd Luippold worked as a lecturer and research associate at the Department of Pharmacology at the University of Tübingen, specializing in preclinical and clinical studies related to diabetic nephropathy.